Intratumoral delivery of engineered recombinant modified vaccinia virus Ankara express-ing Flt3L and OX40L generates potent antitumor immunity through activating the cGAS/STING pathway and depleting tumor-infiltrating regulatory T cells
Yang, N.; Wang, Y.; Liu, S.; Luna, J. M.; Mazo, G.; Tan, A. Y.; Zhang, T.; Wang, J.; Yan, W.; Choi, J.; Rossi, A.; Xiang, J. Z.; Rice, C. M.; Merghoub, T.; Wolchok, J. D.; Deng, L.
Show abstract
Intratumoral (IT) delivery of immune-activating viruses can serve as an important strategy to turn "cold" tumors into "hot" tumors, resulting in overcoming resistance to immune checkpoint blockade (ICB). Modified vaccinia virus Ankara (MVA) is a highly attenuated, non-replicative vaccinia virus that has a long history of human use. Here we report that IT recombinant MVA (rMVA), lacking E5R encoding an inhibitor of the DNA sensor cyclic GMP-AMP synthase (cGAS), expressing a dendritic cell growth factor, Fms-like tyrosine kinase 3 ligand (Flt3L), and a T cell co-stimulator, OX40L, generates strong antitumor immunity, which is dependent on CD8+ T cells, the cGAS/STING-mediated cytosolic DNA-sensing pathway, and STAT1/STAT2-mediated type I IFN signaling. Remarkably, IT rMVA depletes OX40hi regulatory T cells via OX40L/OX40 interaction and IFNAR signaling. Taken together, our study provides a proof-of-concept for improving MVA-based cancer immunotherapy, through modulation of both innate and adaptive immunity. One Sentence SummaryIntratumoral delivery of recombinant MVA for cancer immunotherapy
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- IL-3-driven T cell-basophil crosstalk enhances anti-tumor immunity 97%
- Suppression of tumor/host intrinsic CMTM6 drives anti-tumor cytotoxicity in a PD-L1 independent manner 97%
- Immune modulation of innate and adaptive responses restores immune surveillance and establishes anti-tumor immunological memory 96%
Similar papers in this journal
- Tumor-derived extracellular vesicles regulate tumor-infiltrating regulatory T cells via the immunoreceptor CD300a 96%
- Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases 96%
- VLA-4 suppression by senescence signals regulates meningeal immunity and leptomeningeal metastasis 96%
Similar papers in this journal
- Cancer cell CCR2 orchestrates suppression of the adaptive immune response 97%
- Activation of the Integrated Stress Response in drug-tolerant melanoma cells confers vulnerability to mitoribosome-targeting antibiotics. 95%
- The RNA m6A reader YTHDF2 controls NK cell anti-tumor and anti-viral immunity 94%
Similar papers in this journal
- Integrin αvβ8 on T cells is responsible for suppression of anti-tumor immunity in multiple syngeneic models and is a promising target for tumor immunotherapy 97%
- Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment 97%
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 97%
Similar papers in this journal
- Elucidating Mechanisms of Antitumor Immunity Mediated by Live Oncolytic Vaccinia and Heat-Inactivated Vaccinia 97%
- The spontaneous neoantigen-specific CD4+ T cell response to a growing tumor is functionally and phenotypically diverse. 96%
- MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.